Literature DB >> 12646637

Transactivation of gp130 in myeloma cells.

Jena D French1, Denise K Walters, Diane F Jelinek.   

Abstract

Receptor transactivation, i.e., interaction between unrelated receptor systems, is a growing theme in cytokine and growth factor signaling. In this study we reveal for the first time the ability of IFN-alpha to transactivate gp130 in myeloma cells. An epidermal growth factor receptor/gp130 chimeric receptor previously shown by us to transactivate endogenous gp130, provided a complementary tool to study the underlying mechanisms of receptor cross-talk. Further analysis revealed that transactivation of gp130 by IFN-alpha did not require the extracellular or trans-membrane domain of gp130. Moreover, transactivation of gp130 was critically dependent upon Janus kinase activation by the initiating receptor and correlated with rapid and sustained Janus kinase 1 and tyrosine kinase (Tyk) 2 tyrosine phosphorylation. Finally, transactivation of gp130 may be a common theme in myeloma cells, perhaps providing a mechanism for enhanced or qualitatively distinct cellular responses to specific stimuli.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646637     DOI: 10.4049/jimmunol.170.7.3717

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.

Authors:  Sherine F Elsawa; Luciana L Almada; Steven C Ziesmer; Anne J Novak; Thomas E Witzig; Stephen M Ansell; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

2.  Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth.

Authors:  Dong-Jun Peng; Minghui Zeng; Ryuta Muromoto; Tadashi Matsuda; Kazuya Shimoda; Malayannan Subramaniam; Thomas C Spelsberg; Wei-Zen Wei; K Venuprasad
Journal:  J Immunol       Date:  2011-04-06       Impact factor: 5.422

3.  An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

Authors:  Karène Mahtouk; Michel Jourdan; John De Vos; Catherine Hertogh; Geneviève Fiol; Eric Jourdan; Jean-François Rossi; Bernard Klein
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

4.  A role for IFN-lambda1 in multiple myeloma B cell growth.

Authors:  A J Novak; D M Grote; S C Ziesmer; V Rajkumar; S E Doyle; S M Ansell
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

Review 5.  Cytokines in the microenvironment of Waldenström's macroglobulinemia.

Authors:  Sherine F Elsawa; Stephen M Ansell
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

Review 6.  Survival and proliferation factors of normal and malignant plasma cells.

Authors:  Bernard Klein; Karin Tarte; Michel Jourdan; Karene Mathouk; Jerome Moreaux; Eric Jourdan; Eric Legouffe; John De Vos; Jean François Rossi
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.